Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H36O11P2 |
| Molecular Weight | 550.4729 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC[C@@H](CC[C@H]1[C@@H](C[C@@H]2CC3=C(C[C@H]12)C=CC=C3OCC(O)=O)OP(O)(O)=O)OP(O)(O)=O
InChI
InChIKey=IERCXWVEMYXPMR-KSSXRGRSSA-N
InChI=1S/C23H36O11P2/c1-2-3-4-7-17(33-35(26,27)28)9-10-18-19-11-15-6-5-8-21(32-14-23(24)25)20(15)12-16(19)13-22(18)34-36(29,30)31/h5-6,8,16-19,22H,2-4,7,9-14H2,1H3,(H,24,25)(H2,26,27,28)(H2,29,30,31)/t16-,17-,18+,19-,22+/m0/s1
| Molecular Formula | C23H36O11P2 |
| Molecular Weight | 550.4729 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412595/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515411/
Curator's Comment: Description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412595/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515411/
Treprostinil (marketed under the trade names Remodulin for infusion) is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) is a disease in which blood pressure is abnormally high in the arteries between the heart and lungs. PAH is characterized by symptoms of shortness of breath during physical exertion. The condition can ultimately lead to heart failure. Treprostinil is a potent oral antiplatelet agent. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. Other studies have shown that treprostinil causes a dose-related negative inotropic and lusitropic effect. No major effects on cardiac conduction have been observed. Treprostinil had high affinity for the Prostaglandin D2 receptor (DP1), Prostaglandin E2 receptor EP2 subtype (EP2) and Prostaglandin D2 receptor (IP) receptors (Ki 4.4, 3.6 and 32 nM, respectively), low affinity for EP1 and EP4 receptors and even lower affinity for EP3, Prostaglandin F (FP) and thromboxane (TP) receptors. Treprostinil has demonstrated a unique effect on PPAR gamma, a transcription factor important in vascular pathogenesis as a mediator of proliferation, inflammation and apoptosis. Through a complementary, yet cyclic AMP-independent pathway, treprostinil activates PPARs, another mechanism that contributes to the anti-growth benefits of the prostacyclin class.
Originator
Curator's Comment: By 1976, Vane and fellow researcher Salvador Moncada published the first paper on prostacyclin, in the scientific journal Nature. The collaboration produced a synthetic molecule which was given the name epoprostenol. But like native prostacyclin, the structure of the epoprostenol molecule proved to be unstable in solution, prone to rapid degradation. This presented a challenge for both in vitro experiments and clinical applications. To overcome this challenge, the research team that discovered prostacyclin was determined to continue the research in an attempt to build upon the success they had seen with the prototype molecule. The research team synthesized nearly 1,000 analogs.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1995 |
32.0 nM [Ki] | ||
Target ID: CHEMBL4427 |
4.4 nM [Ki] | ||
Target ID: CHEMBL1881 |
3.6 nM [Ki] | ||
Target ID: CHEMBL3979 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | REMODULIN Approved UseRemodulin is a prostacyclin vasodilator indicated for: Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%) (1.1) Patients who require transition from Flolan®, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. (1.2) 1.1 Pulmonary Arterial Hypertension Remodulin is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%) [see Clinical Studies (14.1) Launch Date2002 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.54 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24603117 |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TREPROSTINIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
0.71 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24603117 |
0.5 mg 3 times / day multiple, oral dose: 0.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TREPROSTINIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.46 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24603117 |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TREPROSTINIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
6.53 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24603117 |
0.5 mg 3 times / day multiple, oral dose: 0.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TREPROSTINIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.06 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24603117 |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TREPROSTINIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
1.34 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24603117 |
0.5 mg 3 times / day multiple, oral dose: 0.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TREPROSTINIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
9% |
TREPROSTINIL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
20 mg 3 times / day steady, subcutaneous Overdose Dose: 20 mg, 3 times / day Route: subcutaneous Route: steady Dose: 20 mg, 3 times / day Sources: |
unhealthy, 10 years |
Disc. AE: Nausea, Blurred vision... AEs leading to discontinuation/dose reduction: Nausea (1 patient) Sources: Blurred vision (1 patient) |
7.5 mg single, subcutaneous Overdose Dose: 7.5 mg Route: subcutaneous Route: single Dose: 7.5 mg Sources: |
unhealthy, 29 years |
Disc. AE: Circulatory collapse... AEs leading to discontinuation/dose reduction: Circulatory collapse (1 patient) Sources: |
150 ug single, respiratory Highest studied dose Dose: 150 ug Route: respiratory Route: single Dose: 150 ug Sources: |
healthy, 30.3 years Health Status: healthy Age Group: 30.3 years Sex: M+F Sources: |
Other AEs: Cough, Throat irritation... Other AEs: Cough (26 patients) Sources: Throat irritation (26 patients) |
100 mg single, subcutaneous Overdose Dose: 100 mg Route: subcutaneous Route: single Dose: 100 mg Sources: |
unhealthy, 58 years |
Disc. AE: Hypotension, Tachycardia... AEs leading to discontinuation/dose reduction: Hypotension (1 patient) Sources: Tachycardia (1 patient) Arrhythmia ventricular (1 patient) Dyspnea (1 patient) |
36 ug 4 times / day steady, respiratory Recommended Dose: 36 ug, 4 times / day Route: respiratory Route: steady Dose: 36 ug, 4 times / day Sources: |
unhealthy, 7.1 - 19.2 years Health Status: unhealthy Age Group: 7.1 - 19.2 years Sex: M+F Sources: |
Disc. AE: Bronchospasm... AEs leading to discontinuation/dose reduction: Bronchospasm (3 patients) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Blurred vision | 1 patient Disc. AE |
20 mg 3 times / day steady, subcutaneous Overdose Dose: 20 mg, 3 times / day Route: subcutaneous Route: steady Dose: 20 mg, 3 times / day Sources: |
unhealthy, 10 years |
| Nausea | 1 patient Disc. AE |
20 mg 3 times / day steady, subcutaneous Overdose Dose: 20 mg, 3 times / day Route: subcutaneous Route: steady Dose: 20 mg, 3 times / day Sources: |
unhealthy, 10 years |
| Circulatory collapse | 1 patient Disc. AE |
7.5 mg single, subcutaneous Overdose Dose: 7.5 mg Route: subcutaneous Route: single Dose: 7.5 mg Sources: |
unhealthy, 29 years |
| Cough | 26 patients | 150 ug single, respiratory Highest studied dose Dose: 150 ug Route: respiratory Route: single Dose: 150 ug Sources: |
healthy, 30.3 years Health Status: healthy Age Group: 30.3 years Sex: M+F Sources: |
| Throat irritation | 26 patients | 150 ug single, respiratory Highest studied dose Dose: 150 ug Route: respiratory Route: single Dose: 150 ug Sources: |
healthy, 30.3 years Health Status: healthy Age Group: 30.3 years Sex: M+F Sources: |
| Arrhythmia ventricular | 1 patient Disc. AE |
100 mg single, subcutaneous Overdose Dose: 100 mg Route: subcutaneous Route: single Dose: 100 mg Sources: |
unhealthy, 58 years |
| Dyspnea | 1 patient Disc. AE |
100 mg single, subcutaneous Overdose Dose: 100 mg Route: subcutaneous Route: single Dose: 100 mg Sources: |
unhealthy, 58 years |
| Hypotension | 1 patient Disc. AE |
100 mg single, subcutaneous Overdose Dose: 100 mg Route: subcutaneous Route: single Dose: 100 mg Sources: |
unhealthy, 58 years |
| Tachycardia | 1 patient Disc. AE |
100 mg single, subcutaneous Overdose Dose: 100 mg Route: subcutaneous Route: single Dose: 100 mg Sources: |
unhealthy, 58 years |
| Bronchospasm | 3 patients Disc. AE |
36 ug 4 times / day steady, respiratory Recommended Dose: 36 ug, 4 times / day Route: respiratory Route: steady Dose: 36 ug, 4 times / day Sources: |
unhealthy, 7.1 - 19.2 years Health Status: unhealthy Age Group: 7.1 - 19.2 years Sex: M+F Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| major | yes (co-administration study) Comment: Treprostinil plasma AUC and Cmax increased approximately 2-fold when administered with gemfibrozil; Treprostinil AUC decreased by 30% when adminsitered with rifampin; Page: 12,14 |
|||
| minor | weak (co-administration study) Comment: Treprostinil AUC decreased approximately 14%, no effect on Cmax when adminstered with fluconazole; Page: 12,14 |
|||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. | 2012-07-01 |
|
| Inhaled treprostinil and pulmonary arterial hypertension. | 2010-12-03 |
|
| The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part II: Medical Treatment - Study Results. | 2010-11 |
|
| Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. | 2010-07-23 |
|
| Stability and antimicrobial effectiveness of treprostinil sodium in Sterile Diluent for Flolan. | 2010-06 |
|
| Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. | 2010-05-04 |
|
| Gateways to clinical trials. | 2010-05 |
|
| The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension. | 2010-03-04 |
|
| Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. | 2010-01-29 |
|
| Gateways to clinical trials. | 2009-09 |
|
| Primary pulmonary hypertension as a manifestation of adult multi-system mitochondrial disorder. | 2009-04-30 |
|
| A novel catheter system for totally implantable intravenous drug therapy: assessment of catheter function and patency with trepostinil therapy. | 2008-04-02 |
|
| Patient safety challenges in treprostinil therapy. | 2008-04 |
|
| Treatment of a nonhealing saphenous vein harvest graft with treprostinil sodium. | 2008-04 |
|
| Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. | 2008-01 |
|
| Treprostinil for pulmonary hypertension. | 2008 |
|
| Gateways to clinical trials. | 2007-11 |
|
| IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues. | 2007-09-07 |
|
| Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006. | 2007-03-02 |
|
| The Role of PPARs in Lung Fibrosis. | 2007 |
|
| The role of peroxisome proliferator-activated receptors in pulmonary vascular disease. | 2007 |
|
| Treprostinil sodium (Remodulin), a prostacyclin analog, in the treatment of critical limb ischemia: open-label study. | 2006-09-08 |
|
| Gateways to clinical trials. | 2006-09 |
|
| Gateways to clinical trials. | 2006-08-09 |
|
| Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. | 2006-06 |
|
| Gateways to clinical trials. | 2006-03-17 |
|
| Gateways to clinical trials. | 2006-03 |
|
| Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. | 2006-02 |
|
| The prostacyclin analog, treprostinil sodium, provides symptom relief in severe Buerger's disease--a case report and review of literature. | 2006-01-31 |
|
| [The best of clinical cardiovascular pharmacology in 2005]. | 2006-01 |
|
| Gateways to clinical trials. | 2005-12 |
|
| Gateways to clinical trials. | 2005-09 |
|
| Gateways to clinical trials. | 2005-06 |
|
| Gateways to clinical trials. | 2005-04-19 |
|
| Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension. | 2005-04 |
|
| Gateways to clinical trials. | 2004-09-07 |
|
| Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. | 2004-08 |
|
| Gateways to clinical trials. | 2004-06 |
|
| Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion. | 2004-05 |
|
| Treprostinil for pulmonary hypertension. | 2004-03 |
|
| Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension. | 2004-03 |
|
| Gateways to clinical trials. | 2004-03 |
|
| Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. | 2004-01 |
|
| Gateways to clinical trials. | 2003-09 |
|
| Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluents. | 2003-05-01 |
|
| Gateways to clinical trials. | 2002-12 |
|
| Treprostinil sodium Pharmacia. | 2002-04 |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Treprostinil is available in three different formulations and four different routes of administration: Remodulin® (treprostinil sodium, intravenous and subcutaneous administration), Tyvaso® (treprostinil sodium, inhaled administration), and Orenitram® (treprostinil diolamine, oral administration) for the treatment of pulmonary arterial hypertension (PAH).
https://www.ncbi.nlm.nih.gov/pubmed/?term=27286723
1.25 ng/kg/min (initial dose for continuous infusion, dosage should be chronically adjusted depending on clinical response)
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 10:32:00 GMT 2025
by
admin
on
Wed Apr 02 10:32:00 GMT 2025
|
| Record UNII |
99S2PY5BN2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000051119
Created by
admin on Wed Apr 02 10:32:00 GMT 2025 , Edited by admin on Wed Apr 02 10:32:00 GMT 2025
|
PRIMARY | |||
|
LM-105
Created by
admin on Wed Apr 02 10:32:00 GMT 2025 , Edited by admin on Wed Apr 02 10:32:00 GMT 2025
|
PRIMARY | |||
|
830354-49-9
Created by
admin on Wed Apr 02 10:32:00 GMT 2025 , Edited by admin on Wed Apr 02 10:32:00 GMT 2025
|
PRIMARY | |||
|
156104640
Created by
admin on Wed Apr 02 10:32:00 GMT 2025 , Edited by admin on Wed Apr 02 10:32:00 GMT 2025
|
PRIMARY | |||
|
99S2PY5BN2
Created by
admin on Wed Apr 02 10:32:00 GMT 2025 , Edited by admin on Wed Apr 02 10:32:00 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
METABOLITE ACTIVE -> PRODRUG |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|